IXICO PLC
IXI
Company Profile
Business description
IXICO PLC provides neuroscience imaging and biomarker analytics services, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. It operates as an imaging contract research organization, supporting clinical trials for neurological disorders by processing and analyzing imaging data. Its platform is used to measure biomarkers associated with diseases such as Alzheimer's, Huntington's, and Parkinson's.
Contact
15 Long Lane
4th Floor, Griffin Court
LondonEC1A 9PN
GBRT: +44 2037637499
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
79
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during June?
ETFs took centre stage in June alongside renewed interest in beaten down growth names.
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
stocks
Cheap ASX share pays a heavy price for NRL rights
Growth has slowed amid increased competition for viewers and content.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,001.30 | 3.70 | 0.04% |
| CAC 40 | 8,289.85 | 74.80 | -0.89% |
| DAX 40 | 24,949.87 | 164.38 | -0.65% |
| Dow JONES (US) | 52,498.64 | 138.37 | -0.26% |
| FTSE 100 | 10,434.14 | 64.15 | -0.61% |
| HKSE | 24,340.73 | 127.01 | 0.52% |
| NASDAQ | 25,873.18 | 408.43 | -1.55% |
| Nikkei 225 | 67,743.50 | 500.77 | 0.74% |
| NZX 50 Index | 13,651.22 | 71.98 | -0.52% |
| S&P 500 | 7,515.34 | 60.05 | -0.79% |
| S&P/ASX 200 | 8,808.50 | 4.80 | 0.05% |
| SSE Composite Index | 3,967.13 | 53.33 | 1.36% |